Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 12.5 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $3.46 million which beat the analyst consensus estimate of $3.04 million by 13.95 percent. This is a 7.75 percent decrease over sales of $3.75 million the same period last year.